Skip to content

IGM Biosciences

  • About Us
    • Our Company
    • Leadership Team
  • IGM Platform
    • Our IGM Platform
    • Publications
    • Presentations
  • Pipeline & Programs
    • Pipeline
    • Imvotamab
    • IGM-8444
    • IGM-7354
    • IGM-2644
  • Investors & News
  • Join Us
    • Our Culture
    • Open Jobs
  • Contact Us

Archives: Presentations

Presentations

IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion

The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs – November 12-14, 2021

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

PEGS Europe – November 4, 2021

Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

American Association for Cancer Research (AACR) Annual Meeting 2021, Virtual – April 10-15, 2021 – Session: Therapeutic Mechanisms of Novel Anticancer Agent

The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

62nd American Society of Hematology (ASH) Annual Meeting and Exposition – December 5-8, 2020

Targeting IL-15 delivery to PD-L1 Expressing Tumors using an Anti-PDL1 x IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity

Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020

PEGS Europe 2020: Agonist IgM: Anti-Death Receptor 5 IgM Induces Tumor Cell Apoptosis in vitro and in vivo with a Favorable Safety Profile

PEGS Europe Virtual – November 12, 2020 – Program: Novel Targets and Emerging Therapeutic Areas

A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22-24, 2020

Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22–24, 2020 – Session: Antibody Technologies – Experimental and Molecular Therapeutics

A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22–24, 2020 – Session: Therapeutics Antibodies 4 – Immunology

High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

American Society of Hematology (ASH) Annual Meeting – December 7-10, 2019

Posts navigation

Older posts
Newer posts

All content © IGM Biosciences, Inc.    info@igmbio.com    Site Credits

LinkedIn